Literature DB >> 26754823

Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers.

Tuan Hiep Tran1, Anh Ngoc Nguyen2, Jong Oh Kim1, Chul Soon Yong1, Chien Ngoc Nguyen2.   

Abstract

Artesunate-loaded nanostructured lipid carriers (ART-NLCs) were prepared by hot homogenization followed by ultrasonication technique. The optimized ART-NLC demonstrated a particle size of 117.5 ± 6.1 nm, with good stability regarding zeta-potential of  -19.47 ± 0.9 mV and drug entrapment efficiency of 92.93 ± 1.47%. ART-NLC showed good cellular uptake in breast cancer cells, which was confirmed by confocal laser scanning microscopy (CLSM) and flow cytometry analysis. The significantly higher in vitro cytotoxicity of ART-NLCs against human breast cancer MCF-7, MDA-MB-231 cells as compared with the free ART was recorded.  Hoechst 33342 staining indicated that ART-NLC induced higher apoptosis rates in MCF-7 as well as MDA-MB-231cells than free ART.

Entities:  

Keywords:  Anti-cancer; apoptosis; artesunate; control release; lipid nanoparticles

Mesh：

Substances：

Year:  2016        PMID： 26754823     DOI： 10.3109/21691401.2015.1129616

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN： 2169-1401            Impact factor:   5.678


  9 in total

1.  Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells.

Authors:  Zar Chi Soe; Bijay Kumar Poudel; Hanh Thuy Nguyen; Raj Kumar Thapa; Wenquan Ou; Milan Gautam; Kishwor Poudel; Sung Giu Jin; Jee-Heon Jeong; Sae Kwang Ku; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Asian J Pharm Sci       Date:  2018-10-20       Impact factor: 6.598

2.  Artesunate Suppresses the Proliferation and Development of Estrogen Receptor-α-Positive Endometrial Cancer in HAND2-Dependent Pathway.

Authors:  Xianghua Yin; Yan Liu; Jiarui Qin; Yixuan Wu; Jiayan Huang; Qi Zhao; Tingting Dang; Yacui Tian; Ping Yu; Xiyue Huang
Journal:  Front Cell Dev Biol       Date:  2021-01-12

Review 3.  Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Authors:  Zhaowu Ma; Clariis Yi-Ning Woon; Chen-Guang Liu; Jun-Ting Cheng; Mingliang You; Gautam Sethi; Andrea Li-Ann Wong; Paul Chi-Lui Ho; Daping Zhang; Peishi Ong; Lingzhi Wang; Boon-Cher Goh
Journal:  Front Pharmacol       Date:  2021-12-31       Impact factor: 5.810

Review 4.  Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand.

Authors:  Karim Farmanpour-Kalalagh; Arman Beyraghdar Kashkooli; Alireza Babaei; Ali Rezaei; Alexander R van der Krol
Journal:  Front Plant Sci       Date:  2022-02-07       Impact factor: 5.753

5.  Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer: in vitro studies.

Authors:  Mantosh Kumar Singh; Sai Kiran S S Pindiprolu; Bharat Kumar Reddy Sanapalli; Vidyasrilekha Yele; G N K Ganesh
Journal:  RSC Adv       Date:  2019-08-12       Impact factor: 4.036

6.  Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.

Authors:  Kanchan Kumari; Sunita Keshari; Debomita Sengupta; Surendra C Sabat; Sandip K Mishra
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

7.  A Case of Recurrent Hepatocellular Carcinoma Acquiring Complete Remission of Target Lesion With Treatment With Traditional Chinese Medicine.

Authors:  Chen Jianxin; Xu Qingxia; Wang Junhui; Zheng Qinhong
Journal:  Integr Cancer Ther       Date:  2016-07-21       Impact factor: 3.279

8.  Novel nano-pomegranates based on astragalus polysaccharides for targeting ERα-positive breast cancer and multidrug resistance.

Authors:  Bingjie Wang; Chunjing Guo; Yanhui Liu; Guangting Han; Yi Li; Yanchun Zhang; Haiyu Xu; Daquan Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

9.  Effect of artesunate on apoptosis and autophagy in tamoxifen resistant breast cancer cells (TAM-R).

Authors:  Xiaoqing Ding; Wei Yue; Haiyan Chen
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.